drugset / Trial / NCT01642238

Antithrombotic Effects of Ticagrelor Versus Clopidogrel

NCT01642238 ↗

Phase 4 Completed 15 enrolled Juan J Badimon AstraZeneca · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to determine whether treatment with ticagrelor (plus aspirin and bivalirudin) is more effective than treatment with clopidogrel (plus aspirin and bivalirudin).

Timeline

Start
2012-07
Primary completion
2013-03
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clopidogrel Small molecule 600 mg —
Subject Ticagrelor Small molecule 180 mg —
Comparator Aspirin Small molecule 81 mg —
Comparator Bivalirudin Peptide 1.75 mg/kg Intravenous